The SEC asks Novartis, ‘Haven't we met before?’
After settling an FCPA enforcement brought by the SEC in March, Novartis is now under criminal investigation in South Korea for alleged illegal payments to physcians. Should the SEC reopen its investigation?
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
News BriefSEC’s Uyeda: ‘Enforcement is the wrong way’ to handle off-channel communications
The U.S. Securities and Exchange Commission’s Mark Uyeda told an audience of investment advisers that the SEC will no longer prioritize stand-alone enforcement actions for violations of the SEC’s rules on off-channel communications.
-
ArticleSEC and CFTC issue final guidance for cryptocurrency
The U.S. Securities and Exchange Commission and the Commodities Futures Trading Commission have released an official interpretation of how federal laws will apply to cryptocurrencies and their transactions.
-
ArticleSEC gets ball rolling on ending quarterly reporting, as investors urge caution
Disclosure requirements for public companies have ballooned over the decades and need to be reigned in, the three members of the Securities and Exchange Commission (SEC), said Thursday.